Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891435457> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2891435457 abstract "3087 Background: INVAC-1 is an optimized plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT). hTERT is a prototype of shared tumor antigen expressed in more than 85% of human tumors. Telomerase activation is associated with maintenance of telomere length and accounts for the unlimited proliferative capacity of cancer cells. In preclinical models, INVAC-1 triggered Th1-polarized hTERT-specific CD8 + and CD4 + T-cell immune responses and anti-tumor effects. Here, we report clinical and pharmacodynamics results of the first clinical study with INVAC-1 as a single agent in solid tumors. Methods: A 3+3 design phase 1 First in Human study evaluating INVAC-1 given monthly for 3 cycles using electroporation-based intra-dermal (ID) injection was conducted. Primary objectives included safety, tolerability and dose limiting toxicities to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Secondary objectives included immune response and anti-tumor activity. Results: 20 patients (pts) with refractory/progressive solid tumors were enrolled in two centers. 3 escalating doses were studied: 100 µg (3 pts), 400 µg (3 pts) and 800 µg (14 pts). At 3-month data cut-off, no dose limiting toxicities or treatment related SAEs have been reported; no MTD was defined. The most common treatment-related adverse events were grade 1 or 2: asthenia and local reaction at injection site. 12 pts experienced stable disease and clinical benefit. For 10 pts, the treatment was extended beyond the per-protocol 3-month duration, up to nine months for 2 pts. IFN-g polarized anti-hTERT immune responses were detected in 55% of pts, in response to INVAC-1 treatment. Conclusions: Results from this study indicate that INVAC-1 ID was safe, well tolerated and strongly immunogenic at the doses and schedule tested. Early anti-tumor activity has been observed. The RP2D of INVAC-1 is therefore a monthly ID injection of 800 µg. These results encourage a future evaluation of INVAC-1 is solid tumors, as well as in hematologic malignancies, either as monotherapy or in combination with various immunotherapeutic drugs. Clinical trial information: NCT02301754." @default.
- W2891435457 created "2018-09-27" @default.
- W2891435457 creator A5006417997 @default.
- W2891435457 creator A5008609620 @default.
- W2891435457 creator A5013201108 @default.
- W2891435457 creator A5032668871 @default.
- W2891435457 creator A5046459015 @default.
- W2891435457 creator A5050623666 @default.
- W2891435457 creator A5053407239 @default.
- W2891435457 creator A5054939691 @default.
- W2891435457 creator A5058100097 @default.
- W2891435457 creator A5059690857 @default.
- W2891435457 creator A5060518732 @default.
- W2891435457 creator A5062141441 @default.
- W2891435457 creator A5076245121 @default.
- W2891435457 creator A5090993023 @default.
- W2891435457 date "2017-05-20" @default.
- W2891435457 modified "2023-10-18" @default.
- W2891435457 title "Results of a first-in-human phase I study of INVAC-1, an optimized plasmid DNA encoding an inactive form of human telomerase reverse transcriptase (hTERT), in patients with advanced solid tumors." @default.
- W2891435457 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.3087" @default.
- W2891435457 hasPublicationYear "2017" @default.
- W2891435457 type Work @default.
- W2891435457 sameAs 2891435457 @default.
- W2891435457 citedByCount "2" @default.
- W2891435457 countsByYear W28914354572018 @default.
- W2891435457 countsByYear W28914354572020 @default.
- W2891435457 crossrefType "journal-article" @default.
- W2891435457 hasAuthorship W2891435457A5006417997 @default.
- W2891435457 hasAuthorship W2891435457A5008609620 @default.
- W2891435457 hasAuthorship W2891435457A5013201108 @default.
- W2891435457 hasAuthorship W2891435457A5032668871 @default.
- W2891435457 hasAuthorship W2891435457A5046459015 @default.
- W2891435457 hasAuthorship W2891435457A5050623666 @default.
- W2891435457 hasAuthorship W2891435457A5053407239 @default.
- W2891435457 hasAuthorship W2891435457A5054939691 @default.
- W2891435457 hasAuthorship W2891435457A5058100097 @default.
- W2891435457 hasAuthorship W2891435457A5059690857 @default.
- W2891435457 hasAuthorship W2891435457A5060518732 @default.
- W2891435457 hasAuthorship W2891435457A5062141441 @default.
- W2891435457 hasAuthorship W2891435457A5076245121 @default.
- W2891435457 hasAuthorship W2891435457A5090993023 @default.
- W2891435457 hasConcept C104317684 @default.
- W2891435457 hasConcept C125593758 @default.
- W2891435457 hasConcept C153911025 @default.
- W2891435457 hasConcept C156719811 @default.
- W2891435457 hasConcept C22744801 @default.
- W2891435457 hasConcept C502942594 @default.
- W2891435457 hasConcept C54355233 @default.
- W2891435457 hasConcept C552990157 @default.
- W2891435457 hasConcept C67705224 @default.
- W2891435457 hasConcept C71924100 @default.
- W2891435457 hasConcept C86803240 @default.
- W2891435457 hasConcept C94581717 @default.
- W2891435457 hasConceptScore W2891435457C104317684 @default.
- W2891435457 hasConceptScore W2891435457C125593758 @default.
- W2891435457 hasConceptScore W2891435457C153911025 @default.
- W2891435457 hasConceptScore W2891435457C156719811 @default.
- W2891435457 hasConceptScore W2891435457C22744801 @default.
- W2891435457 hasConceptScore W2891435457C502942594 @default.
- W2891435457 hasConceptScore W2891435457C54355233 @default.
- W2891435457 hasConceptScore W2891435457C552990157 @default.
- W2891435457 hasConceptScore W2891435457C67705224 @default.
- W2891435457 hasConceptScore W2891435457C71924100 @default.
- W2891435457 hasConceptScore W2891435457C86803240 @default.
- W2891435457 hasConceptScore W2891435457C94581717 @default.
- W2891435457 hasLocation W28914354571 @default.
- W2891435457 hasOpenAccess W2891435457 @default.
- W2891435457 hasPrimaryLocation W28914354571 @default.
- W2891435457 hasRelatedWork W1988965402 @default.
- W2891435457 hasRelatedWork W2004249786 @default.
- W2891435457 hasRelatedWork W2004750837 @default.
- W2891435457 hasRelatedWork W2062925547 @default.
- W2891435457 hasRelatedWork W2124685071 @default.
- W2891435457 hasRelatedWork W2348010998 @default.
- W2891435457 hasRelatedWork W2361491153 @default.
- W2891435457 hasRelatedWork W2381379160 @default.
- W2891435457 hasRelatedWork W2382672806 @default.
- W2891435457 hasRelatedWork W2412387673 @default.
- W2891435457 hasRelatedWork W2414973544 @default.
- W2891435457 hasRelatedWork W2431518996 @default.
- W2891435457 hasRelatedWork W2947927483 @default.
- W2891435457 hasRelatedWork W3031429470 @default.
- W2891435457 hasRelatedWork W3031847609 @default.
- W2891435457 hasRelatedWork W590442057 @default.
- W2891435457 hasRelatedWork W801749888 @default.
- W2891435457 hasRelatedWork W3029704757 @default.
- W2891435457 hasRelatedWork W3032435965 @default.
- W2891435457 hasRelatedWork W3032452828 @default.
- W2891435457 isParatext "false" @default.
- W2891435457 isRetracted "false" @default.
- W2891435457 magId "2891435457" @default.
- W2891435457 workType "article" @default.